Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 41Carcinoma, Non-Small-Cell Lung 28Lung Neoplasms 8Triple Negative Breast Neoplasms 6Neoplasm Metastasis 6Neoplasms 5Uterine Cervical Neoplasms 4Recurrence 2Mesothelioma 2Lymphoma, Non-Hodgkin 2Carcinoma 2Adenocarcinoma of Lung 2Adenocarcinoma 2Thoracic Neoplasms 1Stomach Neoplasms 1Sarcoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Nonhematologic Malignancies 1Non-Squamous Non-Small Cell Lung Cancer 1Non - Small Cell Lung Cancer NSCLC 1Neuroendocrine Tumors 1NSCLC 1Metatropic dwarfism 1Metastatic HER2-positive Breast Cancer 1Lung Diseases 1Lethal Congenital Contracture Syndrome 2 1HR+HER2- Breast Cancer 1HER2-positive Advanced Breast Cancer 1Desmoplastic Small Round Cell Tumor 1

Interventions

zenocutuzumab 2seribantumab 2pembrolizumab 1patritumab 1osimertinib 1exemestane 1cemiplimab 1Vinorelbine 1Vascular Endothelial Growth Factor A 1Trastuzumab 1Paroxetine 1Paclitaxel 1Letrozole 1Itraconazole 1Fulvestrant 1Erlotinib Hydrochloride 1Docetaxel 1Carboplatin 1Antibodies, Bispecific 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lethal Congenital Contracture Syndrome 2 × Vinorelbine × Clear all
NCT03321981 2024-03-07

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

Merus B.V.

Phase 2 Completed
105 enrolled 23 charts

Lethal Congenital Contracture Syndrome 2

Data powered by HemOnc (CC BY 4.0) Colophon âš¡